The Temozolomide Trial for SDH-deficient GIST Patients

GIST is becoming increasingly diverse. SDH-deficient GIST and paragangliomas often occur in adolescents and young adults. Since these SDH mutations are germline, multiple generations of family members are affected.
Dr. Jason Sicklick of Moores Cancer Center at the University of California San Diego will present a webcast detailing the Phase II study of Temozolomide (TMZ) in advanced SDH-mutant/deficient GIST, a new study available to patients with SDH-deficient GIST.

About the Presenter:

Jason K. Sicklick, MD, FACS, is an Associate Professor of Surgery, Division of Surgical Oncology; and Co-Director, Biorepository and Tissue Technology Shared Resource, Moores Cancer Center at the University of California, San Diego, UC San Diego Health Sciences.

Listen to the Webcast